<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483729</url>
  </required_header>
  <id_info>
    <org_study_id>NP27945</org_study_id>
    <secondary_id>RPU425UD-114254</secondary_id>
    <nct_id>NCT01483729</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This single dose, randomized, open-label, 6 sequence, 3-period, crossover study will evaluate&#xD;
      the relative bioavailability of danoprevir and ritonavir in healthy volunteers. In Part 1,&#xD;
      subjects will be randomized to receive single oral doses of one of three tablet formulations&#xD;
      of danoprevir plus the reference ritonavir formulation, with an at least 7-day washout&#xD;
      between periods. In Part 2, subjects will be randomized to receive single oral doses of one&#xD;
      of three tablet formulations of ritonavir plus the reference formulation of danoprevir, with&#xD;
      at least a 7-day washout betwen periods. The anticipated time on study is up to 30 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Danoprevir bioavailabilty (Tablet Formulation 1) in combination with ritonavir (reference formulation): Area under the concentration-time curve (AUC)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Danoprevir bioavailability (Tablet Formulation 2) in combination with ritonavir (reference formulation): Area under the concentration-time curve (AUC)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Ritonavir bioavailability (Test Formulation 1) in combination with danoprevir (refernce formulation): Area under the concentration-time curve (AUC)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Ritonavir bioavailability (Test Formulation 2) in combination with danoprevir (reference formulation): Area under the concentration-time curve (AUC)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Part 1 A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir</intervention_name>
    <description>Phase 3 Tablet Formulation 1, single oral dose</description>
    <arm_group_label>Part 1 B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir</intervention_name>
    <description>Phase 3 Tablet Formulation 2, single oral dose</description>
    <arm_group_label>Part 1 C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir</intervention_name>
    <description>Reference Phase 2 Tablet Formulation, single oral dose</description>
    <arm_group_label>Part 1 A</arm_group_label>
    <arm_group_label>Part 2 D</arm_group_label>
    <arm_group_label>Part 2 E</arm_group_label>
    <arm_group_label>Part 2 F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>Test Formulation 1, single oral dose</description>
    <arm_group_label>Part 2 E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>Test Formulation 2, single oral dose</description>
    <arm_group_label>Part 2 F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>Reference Formulation, single oral dose</description>
    <arm_group_label>Part 1 A</arm_group_label>
    <arm_group_label>Part 1 B</arm_group_label>
    <arm_group_label>Part 1 C</arm_group_label>
    <arm_group_label>Part 2 D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers, 18 to 45 years of age inclusive&#xD;
&#xD;
          -  Body mass index 18.0 - 32.0 kg/m2, weight &gt;/= 50 kg&#xD;
&#xD;
          -  Healthy status will be defined as absence of evidence of any active or chronic disease&#xD;
             following a detailed medical and surgical history and a complete physical examination&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  Medical history without major, recent or ongoing pathology&#xD;
&#xD;
          -  Females of childbearing potential and males and their female partners of childbearing&#xD;
             potential must agree to use 2 forms of contraception (barrier form plus intrauterine&#xD;
             device and spemicide) during the study and for 90 days after the last drug&#xD;
             administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women or males with female partners who are pregnant or&#xD;
             lactating&#xD;
&#xD;
          -  Positive results for drugs of abuse at screening or prior to admission to the clinical&#xD;
             site during any study period&#xD;
&#xD;
          -  Positive for hepatitis B, hepatitis C or HIV infection&#xD;
&#xD;
          -  Use of hormonal contraceptives (birth control pills, injectable, implantable devices)&#xD;
             within 30 days before the first dose of study medication&#xD;
&#xD;
          -  Routine use of more than 2 g of acetaminophen daily&#xD;
&#xD;
          -  History of clinically significant drug allergy (such as anaphylaxis) or hepatotoxicity&#xD;
&#xD;
          -  History of hypersensitivity to danoptevir, ritonavir, or other protease inhibitors&#xD;
&#xD;
          -  History (within 3 months of screening) of alcohol consumption exceeding 2 standard&#xD;
             drinks per day on average&#xD;
&#xD;
          -  Current enrollment or participation in a clinical trial of an experimental medication&#xD;
             or medical device within 3 months of screening unless agreed upon by the Sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 30, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

